Company Insights

AMPH customer relationships

Explore interactive graphBrowse insights index
AMPH customer relationship map

Amphastar Pharmaceuticals (AMPH): Customer relationships that drive cash flow and concentration risk

Amphastar Pharmaceuticals monetizes by developing, manufacturing and selling injectable, inhalation and intranasal specialty and generic drug products, and by licensing and distribution arrangements that convert clinical assets into recurring product revenue. The company generates the bulk of revenue through product sales routed through large U.S. wholesalers and group purchasing organizations (GPOs), supplemented by distribution agreements (domestic and international), co‑promotion arrangements, and modest contract manufacturing services. For investors, the thesis is straightforward: stable, high‑margin product cash flows underpinned by a concentrated wholesaler/GPO channel, offset by execution risk from customer concentration and the commercial handoffs embedded in several distribution and transition agreements. Learn more about relationship analytics at https://nullexposure.com/.

What matters: concentration, contracting posture and channel maturity

Amphastar’s commercial model is distribution‑centric. The 2024 Form 10‑K shows that a small number of U.S. wholesalers and GPOs account for a large share of net revenues — three customers represented roughly 64% of revenue in 2024 — which makes top‑counterparty relationships both critical and material to near‑term cash flow. Contracting signals are mixed: the company has multiyear distribution and licensing commitments in some cases (including long‑term terms), while many GPO/wholesaler arrangements remain terminable on relatively short notice (60–90 days), producing a hybrid posture of committed growth opportunities and short‑cycle revenue risk. Amphastar’s geography is primarily North America, with select international reach for BAQSIMI and an APAC distributor for select products, implying expansion upside coupled with regulatory and execution complexity.

  • Key operating characteristics: high customer concentration, distribution/distributor reliance, active commercial relationships, a mix of long‑term and short‑notice contracts, and modest but real contract manufacturing revenues.

Explore detailed customer relationships and source references at https://nullexposure.com/.

Relationship inventory — who buys, distributes and co‑promotes Amphastar

Below I cover every customer relationship referenced in Amphastar’s public filings and news disclosures. Each entry is a concise, plain‑English summary with a source reference.

Cencora Inc. (FY2024 — 10‑K)

Amphastar lists Cencora among its major customers, with Cencora accounting for approximately 20% of net revenue in 2024 and a meaningful share of accounts receivable. According to Amphastar’s 2024 Form 10‑K, Cencora is one of the company’s top four customers by revenue and receivables. (Source: Amphastar 2024 Form 10‑K.)

Cardinal Health, Inc. (FY2024 — 10‑K)

Cardinal Health is reported as another major wholesale customer, representing around 19% of revenue for 2024 and significant receivable exposure, underscoring Amphastar’s dependency on large distributors. (Source: Amphastar 2024 Form 10‑K.)

Eli Lilly and Co. (FY2024 — 10‑K)

Amphastar discloses Lilly in its customer concentration table; Lilly represented a smaller but non‑trivial percentage of revenues in 2024 and is central to BAQSIMI commercialization arrangements. (Source: Amphastar 2024 Form 10‑K.)

McKesson Corporation (FY2024 — 10‑K; inferred MCK)

McKesson is another of Amphastar’s top distributors, listed as accounting for approximately 25% of net revenue in 2024, highlighting that the three largest U.S. wholesalers/GPOs together drive a majority of sales. (Source: Amphastar 2024 Form 10‑K.)

Eli Lilly and Company (FY2026 — 8‑K/news report)

An 8‑K disclosure cited by StockTitan notes that BAQSIMI sales during 2024 included $19.2 million in Lilly‑marketed sales under a Transition Service Agreement, with associated cost of sales recognized. This confirms the transitional commercial role Lilly played while BAQSIMI was integrated into Amphastar’s operations. (Source: StockTitan summary of Amphastar 8‑K, reported 2026.)

Lilly (FY2026 — earnings call transcript)

In an earnings‑call transcript, Amphastar management referenced a three‑year marketing commitment tied to Lilly that concludes in July, signaling time‑limited co‑marketing obligations that had supported international BAQSIMI presence. (Source: Q4 2025 Amphastar earnings call transcript published on The Globe and Mail / Motley Fool transcript, 2026.)

Genreach (FY2026 — TradingView news)

Amphastar amended a distribution pact with Genreach to cover Middle East and Southeast Asian countries and named Genreach as the exclusive distributor for Primatene MIST in Greater China, indicating a strategic APAC distribution channel for selected products. (Source: TradingView news summary of Amphastar announcement, 2026.)

Cardinal Health (FY2024 — 10‑K, duplicate entry with CAH)

A second reference to Cardinal Health in the 2024 Form 10‑K reiterates its materiality — Cardinal represented mid‑teens to high‑teens percent of revenue and accounts receivable, consistent with the company’s channel concentration risk. (Source: Amphastar 2024 Form 10‑K.)

MannKind (FY2026 — 8‑K/news report)

Amphastar increased selling and co‑promotion expenses related to BAQSIMI and recorded costs tied to a co‑promotion contract with MannKind, indicating active commercial collaboration on certain respiratory or emergency products. (Source: StockTitan coverage of Amphastar 8‑K, 2026.)

Cencora (FY2024 — 10‑K, duplicate COR entry)

A second Cencora entry in the 10‑K confirms Cencora’s status as the largest single customer by percent of total accounts receivable (23%) and roughly 20% of revenue in 2024, reinforcing concentration risk. (Source: Amphastar 2024 Form 10‑K.)

Lilly (FY2024 — 10‑K, LLY entry)

The 10‑K’s concentration table shows Lilly’s contribution to revenue and receivables across 2022–2024, further documenting the financial impact of BAQSIMI distribution and related transition services during that period. (Source: Amphastar 2024 Form 10‑K.)

McKesson (FY2024 — 10‑K, duplicate CAKFF entry)

A second McKesson reference reiterates McKesson’s large share of accounts receivable (34% of total accounts in the receivable table) and about 25% of revenue, emphasizing the outsized role wholesalers play in the company’s cash conversion cycle. (Source: Amphastar 2024 Form 10‑K.)

Constraints and the operating model — what the disclosures signal

The company‑level constraint signals in Amphastar’s filings present a cohesive picture for investors:

  • Contracting posture: Amphastar operates with a mix of long‑term commitments (including multi‑year agreements and at least one ten‑year term referenced in filing excerpts) and short‑notice, terminable GPO/wholesaler contracts (60–90 days). This produces predictable revenue from committed deals alongside exposure to short‑cycle volume shifts.

  • Concentration and criticality: The top three customers consistently represent roughly 60–65% of revenues, making these relationships material and critical to near‑term profitability and working capital.

  • Geographic maturity: The commercial base is primarily North America, but BAQSIMI and targeted APAC distribution via Genreach indicate deliberate international expansion, implying operational complexity and regulatory execution risk.

  • Relationship roles and maturity: Amphastar’s revenue mix includes sellers, distributors, licensees, manufacturers and service providers. Contract manufacturing and licensing relationships exist but are smaller in dollar scale (manufacturing services contributed under $1 million in recent years), while distribution remains the primary, mature revenue driver.

Takeaway: Investors should weigh durable product economics against concentrated wholesaler exposures and the execution demands of international distribution and co‑promotion transitions.

Explore deeper counterparty analysis and monitoring at https://nullexposure.com/.

Investment implications and next steps

Amphastar offers a straightforward commercial profile: strong cash generation from specialty generics routed through three major wholesalers/GPOs, with incremental growth tied to BAQSIMI commercialization and targeted international distributors. Key risks are concentrated counterparty exposure, transition agreements that shift costs and revenue recognition timing, and the need to successfully scale international distribution without disrupting U.S. margins.

If your thesis depends on reliable cash flow and distribution execution, monitor four items closely: receivables concentration, the post‑Lilly BAQSIMI revenue run‑rate, Genreach commercialization milestones in APAC, and any renewal or termination activity among the top three wholesalers.

For portfolio teams and vendor managers who need continuous visibility into these customer linkages and contract characteristics, start here: https://nullexposure.com/.